FNY Managed Accounts’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

FNY Managed Accounts’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-6,000	Closed	-$156K	–	637
2015 Q1	$156K	Buy	+6,000	New	+$110K	0.13%	86

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

FNY Managed Accounts's HZNP Position: Q2 2015 in Review

FNY Managed Accounts sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2015, closing a stake of 6,000 shares — an estimated $156K sold.

FNY Managed Accounts first reported a position in HZNP in Q1 2015 and held it in 1 quarter. The position peaked at $156K in Q1 2015. 213 funds tracked by Wall St. Rank hold HZNP as of Q2 2015.

FNY Managed Accounts reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2015 after selling out during the quarter.
FNY Managed Accounts sold 6,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2015, an estimated $156K.
FNY Managed Accounts first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 1 quarter.
FNY Managed Accounts's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $156K in Q1 2015.
213 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2015.

Based on FNY Managed Accounts's 13F filing for Q2 2015, filed 30 Jul 2015.